FDA advisers to review, likely recommend COVID-19 vaccines for young children this week
A federal advisory panel is likely this week to recommend two COVID-19 vaccines for the youngest children, as well as a second option for older kids whose access has been limited to Pfizer-BioNTech shots.
According to detailed information made public Friday and Sunday, Food and Drug Administration staff reviewed safety and effectiveness data for the Moderna vaccine for people ages 6 months to 17 years and for the Pfizer-BioNTech vaccine for children ages 6 months through 4 years.
The review was positive, raising no new safety issues or concerns about trial data, most of which had been released by the companies.
An FDA expert advisory panel will hold all-day meetings Tuesday and Wednesday to discuss the data, but the staff review suggests that there will be no major surprises and that the panel will recommend authorization of both vaccines.
https://www.msn.com/en-us/news/us/fda-advisors-to-review-likely-recommend-covid-19-vaccines-for-young-children-this-week/ar-AAYouna
